Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. du Bois on Pazopanib in Advanced Ovarian Cancer

June 1st 2013

Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

Genetic Experts' Views Shift on Testing, Prophylactic Surgery

May 28th 2013

The decision about whether to get tested for a genetic mutation that may predispose a person to certain cancers is a difficult one for many patients to make. Even more difficult for mutation carriers is deciding whether to undergo a prophylactic surgical procedure.

SGO Calls for Broad Changes in Managing Patient Care

May 22nd 2013

The SGO asserts that women with gynecologic cancers frequently receive uncoordinated, fragmented testing and treatment from multiple providers at a variety of sites, often without the involvement of a specialist or supportive services.

Counseling BRCA, Lynch Carriers on Prophylactic Oophorectomy

May 8th 2013

Due to the high lifetime risk of ovarian cancer and the poor ovarian cancer surveillance options available, women who carry BRCA1 or BRCA2 mutations are advised to remove their ovaries and fallopian tubes by age 40 or when childbearing is complete.

Dr. Tanyi Describes a Novel Two-Step Immunotherapy

May 2nd 2013

Janos L. Tanyi, MD, PhD, from the University of Pennsylvania, discusses two phase I studies that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Worldwide Effort Yields Major Advances in Identifying Genetic Risks for Breast, Prostate, and Ovarian Cancer

April 30th 2013

A large, international study has yielded a wealth of new information about genetic alterations that can increase an individual's risk of breast, prostate, and ovarian cancer.

Intraperitoneal Chemotherapy Improves Survival in Ovarian Cancer Patients With Low BRCA1 Levels

April 19th 2013

Patients with epithelial ovarian cancer (EOC) and low levels of the BRCA1 protein had significantly improved overall survival (OS) when their platinum-based chemotherapy was delivered abdominally by injection

US Supreme Court Hears Arguments in BRCA1/2 Patenting Case

April 18th 2013

The question of whether it should be legal to patent genes has reached the US Supreme Court, and the impending decision by the highest federal court in the country could significantly transform the current research landscape.

Selumetinib Is Active, Well-Tolerated Treatment in Low-Grade Serous Ovarian Cancer

March 20th 2013

A phase II study found that the novel small-molecule inhibitor selumetinib is well tolerated and achieved an objective response in patients with low-grade serous carcinoma of the ovary or peritoneum.

Individualized Approach to Treatment for the Elderly Ovarian Cancer Patient

March 14th 2013

Stuart Lichtman, MD, and William Tew, MD, from Memorial Sloan-Kettering Cancer Center, discuss personalizing treatment for elderly patients with ovarian cancer.

Dr. Kandalaft on an Ovarian Cancer Immunotherapy

March 5th 2013

Lana Kandalaft, PharmD, MTR, PhD, from the University of Pennsylvania School of Medicine, describes a study that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Dr. Konner Discusses PARP Inhibitors in Ovarian Cancer

February 4th 2013

Jason A. Konner, MD, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the uncertain path of PARP inhibitors for the treatment of ovarian cancer.

Diabetes Drug May Improve Survival in Patients With Ovarian Cancer

January 30th 2013

The oral diabetic medication metformin may help improve survival in patients with ovarian cancer, according to the results of a retrospective case-control study.

Proto-oncogene Responsible for Ovarian Cancer Metastasis Identified

January 29th 2013

Activation of a signaling pathway involving the proto-oncogene Src is responsible for disease progression and metastasis in cancer and beta blocker drugs could be used to reduce mortality in these patients.

The Future of BRCA1/BRCA2 Testing

January 22nd 2013

A pair of studies could change the way patients are evaluated for mutations of BRCA1 and BRCA2, two cancer susceptibility genes closely associated with breast and ovarian cancers, as well as other tumor types.

Pap Test May Detect Ovarian and Endometrial Cancers

January 10th 2013

New research has found that Papanicolaou smear tests that collect DNA in addition to providing a routine cytologic evaluation may be able to identify mutations associated with ovarian and endometrial cancers.

Potential Targets in Ovarian Cancer Identified

January 8th 2013

Researchers have identified the molecular basis behind two concepts in ovarian cancer that allow tumor stem cells to survive and proliferate even after treatment.

Emerging Agents for the Treatment of Ovarian Cancer

December 22nd 2012

Although the association between VEGF and ovarian cancer has been known for quite some time, researchers are still struggling to use drugs that inhibit VEGF and angiogenesis in patients with the disease.

Cristi Radford on Utilizing Gene Panels in Ovarian Cancer

December 20th 2012

Cristi Radford, MS, CGC, from the Sarasota Memorial Hospital, discusses examining cancer gene panels using next generation sequencing for patients with ovarian cancer.

Bevacizumab PFS Benefit Extends Across Cohorts in AURELIA Trial

November 20th 2012

An exploratory analysis of the phase III AURELIA trial demonstrated that adding bevacizumab (Avastin) to chemotherapy in patients with platinum-resistant ovarian cancer benefited patients across treatment cohorts.